This article was downloaded by: On: 24 January 2011 Access details: Access Details: Free Access Publisher Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37- 41 Mortimer Street, London W1T 3JH, UK

## Journal of Liquid Chromatography & Related Technologies

Publication details, including instructions for authors and subscription information: <http://www.informaworld.com/smpp/title~content=t713597273>



CHROMATOGRAPHY

**LIQUID** 

### Liquid Chromatographic Identification of Urinary Catecholamine Metabolites Adsorbed on Alumina

Takeo Iwamot<sup>a</sup>; Masahiko Yoshiura<sup>a</sup>; Keiji Iriyama<sup>a</sup>

a Division of Biochemistry Central Research Laboratory, The Jikei University School of Medicine, Tokyo, Japan

To cite this Article Iwamot, Takeo , Yoshiura, Masahiko and Iriyama, Keiji(1987) 'Liquid Chromatographic Identification of Urinary Catecholamine Metabolites Adsorbed on Alumina', Journal of Liquid Chromatography & Related Technologies, 10: 6, 1217 — 1235

To link to this Article: DOI: 10.1080/01483918708066764 URL: <http://dx.doi.org/10.1080/01483918708066764>

# PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use:<http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

### LIQUID CHROMATOGRAPHIC IDENTIFICATI-**FICATION OF URINARY CATHECHOLAMINE METABOLITES ADSORBED ON ALUMINA**

**Takeo** Iwamoto, Masahiko Yoshiura, and **Keiji** Iriyama

*Division* of *Biochemistry Central Research Laboratory The Jikei University School of Medicine 3-25-8, Nishi-Shin bashi Minato-ku, Tokyo 105, Japan* 

#### **ABSTRACT**

Human urinary catecholamine metabolites adsorbed on alumina was identified by high-performance liquid chromawith electrochemical detection. Since we found that some catecholamine metabolites interfered with the quantitative determination of other catecholamines such as dopamine, norepinephrine, and epinephrine in human urine samples by the liquid chromatographic method combined with the so-called alumina pretreatment procedure. It was found that alumina could adsorb urinary unidentified electroactive components as well as catecholamines. Some of the unidentified components were found to be uric acid, ascorbic acid, 3,4-dihydroxymandelic acid, **3,4-dihydroxyphenylglycol,** 3-methoxy-4 hydroxymandelic acid, and **3,4-dihydroxyphenylacetic** acid. On the basis of the above information, we have developed a method for the determination of catecholamines in human urine samples by high-performance liquid chromatography with electrochemical detection.

#### **INTRODUCTION**

Recent progress in high-performance liquid chromatography (HPLC) with electrochemical detection (ED) has allowed us to determine physiological catecholamines (CA's) with high sensitivity as well as with good selectivity **(1,2).** A commmon method for the extraction, preconcentration and preliminary purification of CA's in biological samples such as body fluids and mammalian tissues is based on the alumina procedure developed by Anton ans Sayre **(3).** If a constant recovery of each CA can be obtained after the alumina pretreatment of biological samples, the quantitative determination of the biogenic amines can be achieved with good reproducibility. As pointed out by several investigators **(4-6),**  the alumina pretreatment procedure has disadvantages. One of them is that alumina is difficult to standardize. Thus, no two batches can be relied upon to give the same performance. Moreover,adsorption and subsequent desorption of CA's to and from alumina require careful manipulation for yielding a constant recovery. Nevertheless, the alumina pretreatment procedure has been widely used as a routine method because it is easy to performina short periodof time andhas relativelyhigh recoveries of CA's from phsiologic materials. Recently, we have re-examined and determined the optimum condition for extracting and preliminary purifying CA's from biological materials according to the so-called alumina procedure (7-9). During the course of the CA study, as described in our previous study (10), we have recognized that some unidentified peaks appeared in the chromatogram monitored by aid of an electrochemical detector tend to interfere with the quantitative determination of CA's in biological samples. Therefore, we aimed to identify the

unidentified peak components. It is known that the levels of ascorbic acid (AA) and uric acid (UA) in body fluids are extremely high compared to any other naturally occuring electroactive components such as CA's and recognized (10,ll) that the **AA** and UA peaks which appear in a chromatogram monitored amperometrically tend to interfere with the quantitative determination of CA's in biological samples. Rossetti et al. (12) found that UA interfered in the determination of epinephrine (E). Mckay biological samples. Rossetti <u>et al.</u> (12) found that UA interfered in the determination of epinephrine (E). Mckay et al. (13) used AA oxidase to avoid the interference by the AA peak in determining norepinephrine (NE) in brain tissue.

On the basis of the above information, we have used an artificially prepared solution containing dopamine (DM), NE, **El** and AA as a test solution in optimizing the chromatographic conditions for the determination of CA's by HPLC-ECD (10,ll). In addition, we have developed a method for the determination of AA and UA in biological samples by HPLC-ECD (10, 11, 14-16).

In this paper, we have identified urinary electroactive components. In addition, we .have developed a method €or the determination of CA's in human urine by HPLC-ECD .

#### **MATERIALS AND METHODS**

All the experiments were conducted at  $25 + 1^{\circ}C$ , unless otherwise stated.

3 -Hydroxy-4 -methoxymandelic acid (V'MA) , **3** -mthoxy-4 hydroxyphenylacetic acid (VLA), **3,4-dihydroxyphenylglycol**  (DHPG) , 3-methoxy-4 -hydroxyphenylglycol **(MHPG)** , normeta nephrin (NM), and 3-mthoxytyramine (3-MT) were supplied by Sigma Chemical Co. (St. Louis, MO, U.S.A.) and 3 methoxy-4-hydroxymandelic acid (VMA), homovanillic acid (HVA), vanillic acid (VA), and metanephrine (M) were obtained from Nakarai Chemicals Ltd. (Tokyo, Japan). 3,4 dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxymandelic acid (DOMA) were from Aldrich Chemical Co. (Milwaukee, WI, U.S.A.) and Tokyo Kasei Kogyo Co. Ltd. (Tokyo, Japan), respectively. Alumina of analytical reagent grade (70-230 mesh ASTM, Merck & Co. Inc. (Darmstadt, W-Germany) was used without any further treatments. DM, NE, E, UA, AA, and any other chemicals were also purchased from Wako Pure Chemicals Industries Ltd. (Osaka, Japan). All the stock solutions were prepared in 0.1 M hydrochloric acid. All buffers and aqueous solutions were prepared with glass-distilled-deionized water.

**A** constant volume pump (Model 655, Hitachi, [Tokyo, Japan]) pushed mobile phase through a reversed-phase high-performance liquid chromatographic column system. In this study, two different column systems were used for the identification of the unidentified electroactive components adsorbed on alumina. Column system I was a stainless-steel tube (150 mm x 4.6 mm i.d.) packed with Chemcosorb 5-ODs-H (particle size; 5 pm, Chemco Science Co. Ltd.[Osaka, Japan]). Column system I1 was the combination of a 50 mm x 4.6 mm i.d. stainless-steel precolumn packed with Fine SIL C<sub>18</sub> (particle size; 5  $\mu$ m; Jasco [Tokyo, Japan]) and a 150 mm x 4.6 mm i.d. stainlesssteel tube packed with #3057 octadecyl silica gel (particle size; 3 pm, Hitahi [Tokyo, Japan]). When column system I was used, the mobile phase was a 0.1 M acetate buffer ( $CH_3COOH-CH_3COONa$ , pH 5.0) and the flow rate was 1.5 ml/min. Column system I is useful for the complete separation of the above described CA metabolites (17). When column system I1 was employed, a 0.2 M phosphate buffer  $(KH_2PO_4-H_3PO_4$ , pH 2.0) was used as a developing solvent and the flow rate was 1 *.O* ml/min. Column system

#### **URINARY CATECHOLAMINE METABOLITES 1221**

**I1** seems to be useful for the determination of CA's by HPLC-ECD (10). Eluate from each column system was monitored by aid of an electrochemical detector (Model; ECP-1, Kotaki [Funabashi, Chiba, Japan]) set at +800 mV vs. Ag/AgCl. In the electrochemical detector, a glassy carbon plate (GC-20, Tokai Carbon Co. Ltd. [Tokyo, Japan]) was used as a working electrode and electrochemical potential was always positive at the glassy carbon electrode (oxidation mode) relative to the Ag/AgC1. A stainless steel wire was used as a counter electrode. The glassy carbon electrode was hand-polished according to the procedure previously described (18). The column temperature was always 25 ± 1<sup>o</sup>C.

Human urine samples were obtained from healthy male volunteers and a patient with pheochromocytoma after surgery. The urine sample from the patient was provided by Dr. Masato Kumagai (The Jikei University School of Medicine, Tokyo, Japan). The alumina pretreatment procedure was conducted according to the method of Anton ar,d Sayre **(3)** with some modifications. Th typical alumina procedure, which was established for this study after the re-examination, is represented in Fig. 1. An aliquot of the HC1 layer was injected onto the column system for the identification of the unidentified peak components adsorbed on alumina as well as for the determination of  $CA's$  in human urine samples. The recoveries of NE, E, and **DM** after the alumina treatment were estimated to be 84.0 + 1.0%, 60.4 + 1.0%, and 60.6 + 1.0%, respectively. The recovery of UA was found to be 20%. The recovery of AA did not show any constant value, probably due to the fact that the adsorption of AA on alumina is strongly dependent on the concentrations of the vitamin. When column system **I1** was used for the determination of CA's, the minimum detectable quantity of each CA was found to be about 10 pg.



Figure 1, Flow sheet of the alumina treatment procedure for extraction, concentration and preliminary purification of catecholamines. Ten microliters of the HC1 layer were injected onto a column. The alumina procedure was conducted at room temperature  $(25 + 1^{\circ}C)$ , unless otherwise stated.

Tentative identification of the chromatographic peak components was performed on the basis of retention behavior and co-chromatography with the reference compounds.

#### **RESULTS AND DISCUSSION**

Recently, we have developed a method for the determination of CA metabolites in various biological samples by HPLC-ECD (17). As an example, Fig. 2 shows a liquid chromatogram of an artificially prepared sample containing DOMA, VMA, V'MA, DHPG, NM, DOPAC, M, MHPG, VLA, VA, 3-MT, and HVA, when 10 **pl** of the test solution was injected onto the column system **I.** The mobile phase was the acetate buffer (pH 5.0) and the flow rate was 1.5 ml/min. Fig. 3 shows the typical chromatogram obtained by injecting 10 **pl** of the HC1 layer (see Fig.1) prepared from the urine sample obtained from the patient with pheochroinocytoma after operation onto column system **I**  under the same chromatographic conditions as used in Fig. 2. **As** seen in *FIg.* **3,** the peaks of VMA, DHPG, UA, and DOPAC were identified. This observation indicates that alumina can adsorb VMA, DHPG, UA, and DOPAC.

On the basis of the above information, we assumed that some peaks of CA metabolites might interfere with the quantitative determination of DM, NE, and E in human urine samples by HPLC-ECD. Fig. **4** shows a liquid chromatogram of the same HC1 layer as used in Fig. 3 , when **<sup>10</sup> p1** of the sample was injected onto the column system **11.**  Fig. 5 shows a liquid chromatogram of a standard solution containing 250 ng/ml of each CA recorded under the same chromatographic conditions as used in Fig. **4.** As seen in the figure, the peak of each CA was well separated and allowed easy determination of **CA's** in human urine samples. The amounts of NE, E, and DW in the urine obtained from the patient were estimated to be 391 ng/ml. 33.2 ng/ml and 212 ng/ml, respectively. As indicated in Fig. **4,** some of the previously unidentified peak components have been identified as DOMA, DHPG, VMA, and DOPAC. The AA peak has been found between the paeks of NE and E. When the urine sample was stored for several days and aliquot of the sample was injected, the AA peak could not be observed. The peak **X** located between the peaks of DM and UA has not been identified. The peak X



Figure 2. A revesed-phase high-performance liquid chromatogram obtained by injecting 10 **pl** of a test solution containing DOMA, VMA, V'MA, DHPG, NM, DOPAC, MI MHPG, VLA, VA, 3-MT, and **HVA** onto column system **I.** Column system **1** was a stainless-steel tube (150 mm x 4.6 mm i.d.) packed with Chemcosorb 5-ODs-H (particle size, 5 **pm).** The mobile phase was a 0.1 **M** acetate buffer (pH 5.0). The flow rate and column<br>temperature were 1.5 ml/min and 25 + 1<sup>O</sup>C, temperature were 1.5 ml/min and 25 respectively. Abbreviations are defined in the text.



**Figure 3. The typical chromatogram obtained by injecting 10 pl of the** HC1 **layer (see Fig. 1) prepared from the urine sample, which was obtained from the patient with pheochromocytoma, under the same chromatographic conditions as used in Fig. 2.** 



**Figure 4. The typical chromatogram obtained by injecting**  10 **pl of the** HC1 **layer preparation obtained**  from **a healthy male volunteer onto column system 11. The mobile phase was a 0.2 M phosphate buffer (pH 2.0). The flow rate and column temperature were 1.0 mllmin and 25 <sup>1</sup>**OC, **respectively. For further expalnation of the chromatographic conditions, see the text.** 

#### **URINARY CATECHOLAMINE METABOLITES 1227**



**Figure 5. A reversed-phase liquid chromatogram of a test solution containing NE, E, and DM obtained under the same chromatographic conditions as used in Fig. 4.** 

component(s) may interfere with the quantitative determination of **DM** by **HPLC-ECD,** probably due to the so-called column-to-column and lot-to-lot variations. Therefore, we are now aiming to identify the peak **X** component(s).

Figure 6 shows a liquid chromatogram obtained by injecing 10 **pl** of the **HC1** layer prepared from a urine sample, which was obtained from a healthy male volunteer, onto column system I1 under the same chromatographic conditions as used in Figs. 4 and 5. **As** seen, the peaks of NE, **AA, E, DOMA, DHPG, DM, UA, VMA,** and **DOPAC** were identified and several unidentified peaks were observed between the peaks of solvent and **UA.** Those unidentified urinary electroactive peak components also seem to interfere with the quantitative determination of **CA's.** The amounts of **NE, El** and **DM** in the urine sample obtained from the volunteer were estimated to be **47.8** ng/ml, 25.7 ng/ml, and 421 ng/ml, respectively.

**As** described above, we have demonstrated the fact that alumina can adsorb **CA's** as well as other urinary electroactive components such as **UA, AA, DHPG, DOMA, VMA,**  and **DOPAC.** If the constant recoveries of **UA, AA, DOMA, DHPG, VMA,** and **DOPAC** had been able to be obtained after the alumina treatment of human urine samples, the quantitative determination of these compounds might be achieved with good reproducibility. In the cases of **AA, DHPG, DOMA, VMA,** and **DOPAC,** however, the constant recoveries have not been able to be obtained after the treatment. In the case of **UA,** the constant recovery has been obtained after the treatment, although it has not been high (about 20%) (19). Recently, we have determined the regional distribution of **CA's** and **UA** in pheochromocytoma excised from a patient with the tumor by the **HPLC-ECD** method coupled with the alumina treatment procedure (20). The chromatographic examinations have revealed (20)



**Figure 6. The typical reversed-phase liquid chromatogram of the same HCl preparation as used in Fig. 3. Ten microliters of the solution were injected onto the column system I1 under the same chromatographic conditions as used in Figs. 4 and 5. For further explanation, see the text.** 

that those, in which **UA** levels are high, also tend to contain high levels of **E.** 

**As** a preliminary study, we estimated the analytical recoveries of **CA** metabolites after the alumina treatment. Two milliliter of a test solution containing 5 µg each CA metabolite was treated according to the same procedure as illustrated in Fig. 1. The recovery was determined by the same **HPLC-ECD** method employed in Figs. 2 and **3.** The recoveries of **DOMA, VMA, V'MA, DHPG, NM, DOPAC, MI MHPG, VLA, VA,** 3-MT, and **HVA** were estimated to be 20.8%, 36.8%, 34.2%, 2.40%, o.oo%, f1.5%, o.oo%, o.oo%, 45.3%, *18.9%,*  0.00%, and 13.1%, respectively, after the alumina treatment under the present experimental conditions. On the basis of the above observations, we discuss the estimated recoveries after the alumina treatment in relation with the chemical structures of the **CA**  metabolites. **As** pointed out by Anton and Sayre (3) , the ability of alumina to bind substances with two vicinal phenolic hydroxyl groups, i.e. catechol and catechol derivatives, from weakly alkaline solution has been of particular important. However, the adsorption of catechol compounds by alumina is not completely specific. In this study, we have found that the adsorption of **CA's** by alumina is shared by **DOMA, DHPG, VMA, DOPAC, UA, AA,** and any other unidentified electroactive compounds in the **HC1**  layer preparations obtained from human urine samples. This finding seems to give us a hint for the development of a method for preliminary purification and concentration of the electroactive components adsorbed on alumina in biological samples. But it has also found that the adsorption of the **CA** metabolites in biological samples onto alumina is not always quantitative. If the constant recoveries can be always obtained, the quantitative determination of **DOMA, DHPG, VMA,** and **DOPAC** would be

#### **URINARY CATECHOLAMINE METABOLITES 1231**

achieved with good reproducibility by a one-time chromatographic method. **As** demonstrated above, it has been found that **NM, MI** and **3-MT** cannot be adsorbed on alumina under the present experimental conditions, whereas NE, E, and **DM** can be efficiently adsorbed on it. Compared with their chemical structures, **NE, El** and **DM** have a hydroxyl group beside **NM, MI** and **3-MT** have a methoxy group in place of a hydroxyl group (see Fig. 7). Figure 7 represents the chemical structures of **CA's** and thier metabolites. **DOPAC, DOMA,** and **DHPG** have two vicinal phenolic hydroxyl groups in their respective chemical structures. In fact, **DOPAC** and **DHPG** are relatively well adsorbed on alumina. However, the recovery of **DHPG** after the alumina treatment has been found to be small compared with those of **DOPAC** and **DOMA. As** seen in Fig. 7, **DOPAC**  and **DOMA** have a carboxyl group in their respective chemical structures, whereas **DHPG** have no carboxyl group. The carboxyl group can be ionized to form **COO-** and **H+** in neutral and alkaline media and the **CA** metabolites having a carboxyl group in their chemical structures can be efficiently adsorbed on alumina. We assumed that the **CA**  metabolites, which have the m-hydroxyl and carboxyl groups in their respective chemical structures can be adsorbed on alumina with high efficiencies. In fact, **HVA, VA, VLA,** and **VMA,** which have both functional groups in their chemical structures, have found to be well adsorbed on alumina. On the contrary, **MHPG, NM,** M, **N,** and **3-MT,**  which have neither a m-hydroxyl group nor a carboxyl group in their chemical structure, have been scarcely adsorbed on alumina showing that the recoveries of these **CA** metabolites are negligible. On the basis of the above information, we speculate that the **CA** metabolite, which have at least two negatively charged functional groups such as **-COO-** and *-0-* in alkaline media can be adsorbed





on alumina. This speculation seems to be consistent with our experimental results on the recoveries of twelve CA metabolites after the alumina treatment demonstrated above .

As described above, DOPAC, DOMA, HVA, VA, VLA, VMA, and DHPGcanbeadsorbedonaluminainalkaline media. We are now aiming to optimaize the alumina treatment procedure for extracting, preliminary concentrating and purifying these CA metabolites in biological samples.

#### **REFERENCES**

- 1. Kissinger, P.T., Refshauge, C., Drelling, R., and<br>Adams, R.N., "An electrochemical detector for liquid chromatography with picogram sensitivity", Anal. Lett., *6,* 465-477, 1973.
- **2.**  Kissinger, P.T., "Electrochemical detection in liquid chromatography and flow injection analysis".<br>In: Laboratory Techniques in Electroanalytical Laboratory Techniques in Electroanalytical Chemistry, Ed. by P.T. Kissinger and W.R. Heineman. New York and Basel, Marcel Dekker, Inc., 1984, pp. 61 1-635.
- **3.**  Anton, A.H. and Sayre, D.F., "A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholfactors affecting the aluminum oxide-trihydroxy-<br>indole procedure for the analysis of catechol-<br>amines", J. Pharmacol. Exp. Ther., <u>138</u>, 360-375,<br>1962. 1962.
	- 4. Higa, S., Suzuki, T., Hayashi, A. Tsuge, I. and Yamamura, Y., "Isolation of catecholamines in biological fluids by boric gels", Anal. Biochem., Higa, S., Suzuk<br>Yamamura, Y., '<br>biological flui<br>77,18-24,1977.
	- **5.**  Knox, J.H. and Jurand, J., "Separation of catecholamines and their metabolites by adsorption, ion-pair and soap chromatography", J. Chromatogr.,<br>125, 89-101, 1976.  $\frac{77}{16}$ ,  $18-24$ ,  $1977$ .<br>
	Knox, J.H. and<br>
	catecholamines and<br>
	ion-pair and soap<br>
	125, 89-101, 1976.
	- 6. Wright, J.T., **"A** rapid quantitative method for chemical estimation of urinary catecholamines in diagnosis of pheochromocytoma", Lancet, **2,** <sup>11</sup>**55-**  1157, 1958.
- 7. Iwamoto, T., Yoshiura, M., Ozaki, Y. and Iriyama, K., "Re-examination of an alumina procedure for the preliminary purification of urinary catecholamines", Jikeikai Med. J., 29, 361 -371 , 1982.
- 8. Iriyama, K., Yoshiura, M., and Iwamoto, T., "Determination of catecholamines in rat tissues by highperformance liquid chromatography with electrochemical detection", *30,* 35-43, 1983.
- **9.**  Iwamoto, T. Yoshiura, M., and Iriyama, K., "Liberation of catecholamines from alumina", Jikeikai Med. J., *30,* 123-128, 1983.
- 10. Iriyama, K., Yoshiura, M., and Iwamoto, T., "Electrochemical detection of ascorbic and uric acids in the eluate from reversed-phase highperformance liquid chromatography with newly developed rigid-type porous polymer packing (polymetacrylate gels)", J. Liq. Chromatogr., <u>8</u>, 333-444, 1985.
- 11. Yoshiura, M., Iwamoto, T., and Iriyama, K., "Liquid chromatographic determination of catecholamines, ascorbic acid, and uric acid in mammalian tissues", Jikeikai Med. J., *32,* 21 **-31** , 1985.
- 12. Rossetti, Z.L., Mercuro, G., and Rivano, C.A., "A study of the parameters affecting flow gradient analysis of catecholamines, DOPA and DOPAC by ion pair liquid chromatography with electrochemical detection", Life Sci., 33, 2387-2397, 1983.
- 13. Mckay, L., Bradberry, C., and Oke, A., "Ascorbic acid oxidase speeds up analysis for catecholamines, indolamines and their metabolites in brain tissue using high-performance liquid chromatography with electochemical detection", J. Chromatogr., 311, 167-169, 1984.
- 14. Iriyama, K., Yoshiura, M., Iwamoto, T., and Ozaki, Y., "Simultaneous determination of uric and ascorbic acids in human serum by reversed-phase highperformance liquid chromatography with electrochemical detection", Anal. Biochem., 141, 238-243, 1984.
- 15. Aoki, T., Yoshiura, M., Iwamoto, T., and Iriyama, **K.,** "Postmortem changes of uric acid in various rat tissues: Determination of uric acid by reversedphase high-performance liquid chromatography with electrochemical detection", Anal. Biochem., 143,<br>113-118, 1984.
- 16. Yoshiura, **M.,** and Iriyama, K., "Simultaneous determination of ascorbic and uric acids in body fluids by high-performance liquid chromatography with electrochemical detection", J. Liq. Chromatogr., *9,*  177-1 88, 1986.
- 17. Iwamoto, T., Yoshiura, M., and Iriayma, K., to be published elsewhere.
- 18. Iriyama, K., Iwamoto, T., and Yoshiura, M., "Liquid chromatographic determination of glutathione with electrochemically pretreated glassy carbon electrode", J. Liq. Chromatogr., **2,** 955-969, 1986.
- 19. Iwamoto, T., Yoshiura, **PI.,** and Iriyama, K., "Analytical recovery of uric acid in rabbit-brain tissues as determined by liquid chromatography", Jikeikai Med. J., *3l,* 269-275, 1984.